BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 6364366)

  • 1. A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma.
    Benson RC; Gill GM; Cummings KB
    Semin Oncol; 1983 Sep; 10(3 Suppl 3):43-5. PubMed ID: 6364366
    [No Abstract]   [Full Text] [Related]  

  • 2. Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer.
    Benson RC; Cummings K
    Prog Clin Biol Res; 1989; 303():177-86. PubMed ID: 2674984
    [No Abstract]   [Full Text] [Related]  

  • 3. Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer.
    Murphy GP; Huben RP; Priore R
    Urology; 1986 Jul; 28(1):36-40. PubMed ID: 3523938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of plasma testosterone and prolactin changes in advanced cancer of prostate treated with diethylstilbestrol or estramustine phosphate.
    Morales A; Nickel JC
    Urology; 1985 Nov; 26(5):477-81. PubMed ID: 3904134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estramustine phosphate compared with diethylstilbestrol. A randomized, double-blind, crossover trial for stage D prostate cancer.
    Benson RC; Gill GM
    Am J Clin Oncol; 1986 Aug; 9(4):341-51. PubMed ID: 3529921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. French multicenter study on the use of estramustine phosphate versus diethylstilbestrol.
    Hauchecorne J
    Prog Clin Biol Res; 1987; 243B():229-34. PubMed ID: 3309983
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer.
    Smith PH; Suciu S; Robinson MR; Richards B; Bastable JR; Glashan RW; Bouffioux C; Lardennois B; Williams RE; de Pauw M
    J Urol; 1986 Sep; 136(3):619-23. PubMed ID: 3525866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EORTC Phase III trials in prostatic cancer.
    Robinson MR; Smith PH; Macaluso MP; Sylvester R; de Voogt H
    Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132
    [No Abstract]   [Full Text] [Related]  

  • 9. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
    Nickel CJ; Morales A
    Can J Surg; 1983 Sep; 26(5):434-8. PubMed ID: 6351988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experiences with estramustine phosphate (Estracyt, Emcyt) in prostate cancer.
    Murphy GP; Slack NH; Mittelman A
    Semin Oncol; 1983 Sep; 10(3 Suppl 3):34-42. PubMed ID: 6364365
    [No Abstract]   [Full Text] [Related]  

  • 11. Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of Protocol 30762.
    Smith PH; Robinson M; Richards B; Suciu S; De Pauw M; Sylvester R; Denis L
    Urology; 1984 Jun; 23(6 Suppl):64-8. PubMed ID: 6375083
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of flutamide and Emcyt in hormone-refractory metastatic prostatic cancer.
    de Kernion JN; Murphy GP; Priore R
    Urology; 1988 Apr; 31(4):312-7. PubMed ID: 3281365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change in white cell count during treatment of advanced cancer of the prostate with estramustine phosphate and with stilboestrol.
    Daponte D; Sylvester R; De Pauw M; Fryszman A; Smith RM; Smith PH
    Br J Urol; 1983 Aug; 55(4):408-12. PubMed ID: 6349745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estramustine phosphate as primary therapy for metastatic prostate cancer. Preliminary results of the University of Wisconsin trial.
    Benson RC
    Urology; 1984 Jun; 23(6 Suppl):69-72. PubMed ID: 6375084
    [No Abstract]   [Full Text] [Related]  

  • 15. [Plasma changes caused by estrogens in the vascular risk of prostatic carcinoma over a 3-year period].
    Daponte DP; Stevens I; Robinson MR
    Actas Urol Esp; 1986; 10(6):437-40. PubMed ID: 3825644
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomised, double-blind study of estramustine phosphate and leuprolide acetate.
    De la Grange AB
    Prog Clin Biol Res; 1987; 243B():227-8. PubMed ID: 3116555
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
    Kalland T; Haukaas S
    Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estramustine for prostate cancer.
    Med Lett Drugs Ther; 1982 Aug; 24(615):74. PubMed ID: 7099111
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma hormone levels in patients with prostatic carcinoma treated with diethylstilboestrol and estramustine.
    Bishop MC; Selby C; Taylor M
    Br J Urol; 1985 Oct; 57(5):542-7. PubMed ID: 3904908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
    Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
    J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.